University of Tsukuba

Gc Corporation

Shigeru Chiba

Mamiko Yanagimoto

Shinichi Kojima

Akihiro Fujii

Seishi Ogawa

The present invention provides a therapeutic agent and others for various tumors including angioimmunoblastic T-cell lymphoma (AITL), which is an orphan disease. The present invention relates to a therapeutic agent and others for tumors identified by phosphorylation of a proto-oncogene protein belonging to the VAV family, which comprises dasatinib or a prodrug thereof or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof as an active ingredient.

Therapeutic agent for tumors identified by phosphorylation of proto-oncogene protein belonging to VAV family

A locking member that locks a mixing nozzle to a cartridge that includes two syringes, the mixing nozzle being configured to mix the materials from the two syringes within the nozzle as the materials are discharged. The locking member includes a support rod supported on the mixing nozzle that is displaceable in a direction orthogonal to the direction in which the nozzle extends, and first and second engaging parts that engage with horizontal parts provided on the cartridge. The locking member further includes an inclined part that is inclined toward the opposite side to the nozzle, and that is provided between at least one of the first engaging part and the second engaging part, or between the second engaging part and the other end of the support rod.

Locking member, mixing tip, and double syringe

A method for detecting T-cell lymphoma characterized in that gene mutations of at least one base selected from a group comprising base numbers 50, 331, 334, and 482 or gene mutations of base numbers 49 to 51 in the base sequence of an RHOA gene collected from a subject are analyzed, and the analysis results and T-cell lymphoma are associated with each other.

Growing community of inventors

Ibaraki, Japan

Shigeru Chiba